Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
Paula T. Trzepacz(Indiana University School of Medicine), Constantine G. Lyketsos(Johns Hopkins University), Linda B. Tabas(Eli Lilly (United States)), Thomas J. Konechnik(Eli Lilly (United States)), Jeffrey L. Cummings(University of California, Los Angeles), Curtis Chang(Eli Lilly (United States)), Ellen B. Dennehy(Purdue University West Lafayette), Tammy Forrester(Eli Lilly (United States)), Catherine L Shuler(Eli Lilly (United States)), Brian A. Willis(Eli Lilly (United States))
Cited by 51
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
Mood Disorders in the Medically Ill: Scientific Review and Recommendations
|Biological Psychiatry|2005|1.1k
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989